Prospective Study of Changes in Anti-HCV Immunoglobulin G Antibody Titers after Treatment with Direct Acting Antiviral Agents
Journal Title: The Egyptian Journal of Hospital Medicine - Year 2018, Vol 73, Issue 1
Abstract
Introduction: worldwide, approximately 180 million people are living with CHC, which corresponds to a global prevalence of 1.1% and millions more are newly infected each year. Annually, 700.000 people die from HCV-related complications, including cirrhosis and hepatocellular carcinoma (HCC). Aim of the work: the present study investigated the dynamics of change in various HCV antibodies in patients with CHC who achieved SVR after DAAs. Methodology: this was a prospective case-control study that was conducted on 150 patients. They were categorized into three main groups: Group I: included 100 patients with chronic HCV infection as diagnosed by SRT-PCR. They were submitted to treatment with DAAs for 12 weeks. Group II (positive control group): Included 25 patients who presented with CHC infection as diagnosed by positive anti-HCV IgG antibodies and positive HCV SRT-PCR, but either refuse or postpone HCV therapy or the treatment of HCV itself was contraindicated. Group III (negative control group): included 25 patients, apparently healthy individuals who test positive for anti-HCV IgG antibodies, but negative HCV SRT-PCR. HCV IgG Ab titers was assessed by commercially available third-generation enzyme-linked immunosorbent assay (ELISA) at base line, end of treatment and then at the 24th week (i.e. 12 weeks after the end of treatment). Results: as regard HCVAb, it showed a significant statistical difference (pvalue < 0.001) between titer results at baselin12th week and 24th week in patients group I; as HCV Ab titers were 3.3 ± 0.2 mg/dl at baseline and declined to 2.7 ±0.2 at 12th week and 2.4± 0.3 at 24th week. But, there was no statistical significant difference (p-value > 0.05) between HCV Ab titer results at baseline, 12th week and 24th week in the studied positive control patients group II as HCV Ab titers were 3.1 ± 0.2 at baseline, 3.2 ±0.2 at 12th week and (3.2± 0.1) at 24th week week. Also, there was no statistical significant difference (p-value > 0.05) between HCV Ab titer results at baseline, 12th week and24th week in studied negative control patients group III as HCV Ab titers were 1.22 ± 08 at baseline, (1.23±0.08) at 12th week and 1.24± 0.07 at 24th week. Conclusion: HCV antibody titer appeared to continue to decrease after eradication of HCV by DAAs therapy.
Authors and Affiliations
Eman Helal
Keywords
Related Articles
- EP ID EP547635
- DOI -
- Views 133
- Downloads 0
Estimation of Serum Ferritin Level in Preterm Labour
Background: Preterm birth is the leading cause of newborn deaths and also the leading cause of death in children under 5 years of age. There is wide spread suspicion that subclinical infection is a common accompaniment a...
Effect of Silver nanoParticles on Carbapenem Resistant Gram-negative Bacteria
<span>Background: </span><span>Gram-negative bacteria are common causes of both community-acquired and hospital-acquired infections. </span><span>β</span><span>-Lactam drugs are often the primary therapeutic option for s...
Correlation between T Stage of the Tumor and Tumor Behavior in Locally Advanced Head and Neck Squamous Cell Carcinoma
<strong>Background: </strong>Head and neck cancer (HNC) represents more than 550,000 cases annually. It accounts for 380,000 deaths every year. Despite aggressive treatment, only 35% to 55% of patients who present with l...
Impact of Kangaroo Position on Serum Nitric Oxide in Preterm Infants
Background: Kangaroo mother care is a standardized protocol-based care for preterm and low birth weight infants. The core feature is early positioning of the infant, prone and upright on the mother or father’s chest to m...
Assessment of Cases of Acute Tramadol Toxicity as Regards Clinical, Laboratory and Management Procedures in Some University Hospitals in Cairo
<span>Tramadol, a widely used opioid in recent years, is a centrally acting analgesic drug that has been used clinically for the last two decades to treat pain in humans. Tramadol also has antitussive activity. Tramadol...